XRTX — XORTX Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1729214 ·
Last close
$1.06
Market Cap
$1.93M
52W High
$3.60
52W Low
$0.81
ADV30
1,183,695
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,690,650 | -1,690,734 | 6,184,197 | 994,045 | 679,522 |
| Mar 2026 | 0 | — | -823,297 | -808,472 | 2,144,791 | 250,275 | 860,988 |
| Dec 2025 | 0 | — | -686,416 | -590,462 | 2,683,530 | 864,514 | 599,071 |
| Sep 2025 | 0 | — | -716,197 | -649,469 | 2,811,078 | 1,193,915 | 837,408 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,100,467
Investing CF
$-417,123
Financing CF
$5,456,493
CapEx
$-177,393
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.23
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-26,323,763
Inventory
—
Receivables
$88,090
ST Investments
—
EBIT TTM
$-3,916,560
Pretax Income TTM
$-3,739,137
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,256,014 | -2,656,304 | 2,683,530 | 599,071 | 2,084,459 | -2,768,723 |
| Dec 2024 | 0 | -4,118,319 | -3,313,346 | 4,094,527 | 757,990 | 3,336,537 | -3,678,648 |
| Dec 2023 | 0 | -6,045,986 | -2,158,065 | 5,467,964 | 825,938 | 4,642,026 | -6,583,165 |
| Dec 2022 | 0 | -10,290,606 | -7,718,882 | 12,374,026 | 5,377,215 | 6,996,811 | -8,165,959 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PPCB | Propanc Biopharma, Inc. | $1.94M | $1.88 | — |
| ACUT | Accustem Sciences Inc. | $1.90M | $0.12 | — |
| JAGX | Jaguar Health, Inc. | $1.96M | $0.38 | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $1.88M | $0.53 | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $2.00M | $1.52 | — |
News headlines (Yahoo Finance, 1h cache)
XORTX Completes Manufacturing of Clinical Drug Supply
2026-11-16 13:05 · Yahoo
XORTX Patent Allowed for XRx-101 Program by Japan Patent Office
2026-11-13 17:00 · Yahoo
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
2026-09-10 20:05 · Yahoo
XORTX Re-Engages Investor Relations Program
2026-09-08 22:15 · Yahoo
XORTX Announces Termination and Postponement of Investor Relations Program
2026-08-28 11:00 · Yahoo
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
2026-10-08 20:00 · Yahoo
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
2026-09-18 12:05 · Yahoo
XORTX Announces Director Resignation
2026-07-31 21:00 · Yahoo
XORTX Appoints New Director
2026-07-29 11:00 · Yahoo
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
2026-06-15 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.